BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 23361103)

  • 1. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance.
    Gonzalez de Castro D; Clarke PA; Al-Lazikani B; Workman P
    Clin Pharmacol Ther; 2013 Mar; 93(3):252-9. PubMed ID: 23361103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?
    Hawkes E; Cunningham D
    Lancet Oncol; 2010 Nov; 11(11):1020-1. PubMed ID: 21051017
    [No Abstract]   [Full Text] [Related]  

  • 4. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma.
    Rebecca VW; Smalley KS
    Expert Opin Investig Drugs; 2011 Feb; 20(2):137-40. PubMed ID: 21235427
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug-biomarker co-development in oncology - 20 years and counting.
    Twomey JD; Brahme NN; Zhang B
    Drug Resist Updat; 2017 Jan; 30():48-62. PubMed ID: 28363335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomic biomarkers for personalized cancer treatment.
    Rodríguez-Antona C; Taron M
    J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming implementation challenges of personalized cancer therapy.
    Meric-Bernstam F; Mills GB
    Nat Rev Clin Oncol; 2012 Sep; 9(9):542-8. PubMed ID: 22850751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized therapy for lung cancer: striking a moving target.
    Pakkala S; Ramalingam SS
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
    Lin PS; Semrad TJ
    Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine.
    Tarhini A; Kudchadkar RR
    Cancer Treat Rev; 2018 Dec; 71():8-18. PubMed ID: 30273812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Companion biomarkers: paving the pathway to personalized treatment for cancer.
    Duffy MJ; Crown J
    Clin Chem; 2013 Oct; 59(10):1447-56. PubMed ID: 23656699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized oncology in interventional radiology.
    Abi-Jaoudeh N; Duffy AG; Greten TF; Kohn EC; Clark TW; Wood BJ
    J Vasc Interv Radiol; 2013 Aug; 24(8):1083-92; quiz 1093. PubMed ID: 23885909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers.
    Miranda F; Prazeres H; Mendes F; Martins D; Schmitt F
    Mol Biol Rep; 2022 Jan; 49(1):717-733. PubMed ID: 34739691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired Resistance Is Oncogene and Drug Agnostic.
    Doebele RC
    Cancer Cell; 2019 Oct; 36(4):347-349. PubMed ID: 31614114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy.
    Wu D; Wang DC; Cheng Y; Qian M; Zhang M; Shen Q; Wang X
    Semin Cancer Biol; 2017 Feb; 42():13-19. PubMed ID: 27840278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive biomarkers in precision medicine and drug development against lung cancer.
    Fang B; Mehran RJ; Heymach JV; Swisher SG
    Chin J Cancer; 2015 Jul; 34(7):295-309. PubMed ID: 26134262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
    Montagut C; Sharma SV; Shioda T; McDermott U; Ulman M; Ulkus LE; Dias-Santagata D; Stubbs H; Lee DY; Singh A; Drew L; Haber DA; Settleman J
    Cancer Res; 2008 Jun; 68(12):4853-61. PubMed ID: 18559533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards precision oncology in RET-aberrant cancers.
    Subbiah V; Roszik J
    Cell Cycle; 2017 May; 16(9):813-814. PubMed ID: 28318386
    [No Abstract]   [Full Text] [Related]  

  • 20. Is biomarker research advancing in the era of personalized medicine for head and neck cancer?
    Yokota T
    Int J Clin Oncol; 2014 Apr; 19(2):211-9. PubMed ID: 24442754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.